Radicle Science, a healthtech B corporation specializing in validating health and wellness products, will launch what’s being called the first large-scale, blinded, placebo-controlled clinical trials on rare cannabinoids, including THCV, CBN, CBG and CBC.
The trials – dubbed Radicle Discovery – will study those cannabinoids’ effects on energy, focus, appetite, sleep disturbance, pain, stress and anxiety. According to Radicle Science, these are unprecedented studies that will involve more than 10,000 participants and are set to kick off soon.
Radicle Science closed out 2021 with the ground-breaking completion of 25 randomized controlled trials (RCTs) of cannabinoid products, including history’s largest CBD RCT. The Radicle Real World Evidence (RWE) studies, involving over 7,000 participants, examined various formulations of CBD-containing products and their effect on key health outcomes across five domains including general well-being, quality of life, sleep quality, pain, and feelings of stress and anxiety.
In the first half of 2022, Radicle Science will continue to conduct rigorous clinical trials on CBD products for pain, sleep disturbance, stress and anxiety, while also commencing history’s first blinded, randomized, placebo-controlled clinical trials on rare cannabinoids for various conditions such as:
- Effect of CBG on stress, anxiety, pain and sleep disturbance
- Effect of CBC on pain, anxiety and sleep disturbance
- Effect of CBN on sleep disturbance, stress, anxiety and pain
- Effect of THCV on energy, focus and appetite
Brands participating in various portions of the clinical trials include Columbia Care, Lord Jones, Open Book Extracts, Straight Hemp, Trokie and Wana Brands.
“We are headed for exponential growth in 2022 as we prepare to study 10 times more people than we did in 2021,” said Radicle Science co-founder and CEO Dr. Jeff Chen.
People from diverse backgrounds, demographics and ages are encouraged to sign up to participate in a Radicle study.
Radicle Science is excited to share knowledge with consumers, regulators, manufacturers and healthcare providers from the aggregate anonymized data across its studies and to join conversations surrounding the future of cannabinoid clinical research.
“We aim to support our mission of creating a movement that redefines the research paradigm and enables evidence-based decision making across the health and wellness industry, starting with cannabinoids,” explained Chen.
Among the industry events that Radicle Science co-founders Chen and Pelin Thorogood will be speaking in 2022 are:
- Cornell University 2022 Predictions Dinner
- CannMed 2022
- Emerald Conference
- Radicle ACES webinar, featuring special guests Gavin Chandler, CEO of Trokie® and Rosemary Mazanet, MD, PhD, CSO of Columbia Care
- Council for Cannabis Federal Regulation (CFCR) March webinar
- Financial Times FTWeekend Festival
- New York University Big Ideas: The Emerging Cannabis Industry
In 2021, Radicle Science worked with dozens of industry leading cannabinoid brands, studying more participants across these RCTs than all worldwide cannabinoid RCTs combined that year, resulting in over 2M health outcome data points.